BET inhibitors have been proposed as suppressors of tumorigenesis in several types of cancers (Cheng et al., 2013; Puissant et al., 2013; Shi et al., 2014); among these, apabetalone (RVX‐208; Resverlogix, Calgary, Canada; T3E6L1) is the most advanced in terms of clinical development. Here, DNER is linked to cancer.